TIDMFIPP
Frontier IP Group plc
07 May 2020
RNS Reach
AIM: FIPP
07 May 2020
Frontier IP Group plc
("Frontier IP" or the "Group")
Portfolio news - Exscientia and SRI International enter
collaboration to accelerate drug discovery through automation and
artificial intelligence
Frontier IP, a specialist in commercialising intellectual
property, notes that portfolio company Exscientia ("Exscientia" or
the "Company"), a world leader in AI-driven drug discovery, has
entered into a collaboration with US research centre SRI
International ("SRI") to expedite discovery of selective molecules
for a high value oncology target.
The collaboration will see the two companies implement a new
approach to drug discovery by integrating SRI's fully automated
synthetic-chemistry system with Exscientia's Centaur Chemist(TM)
system.
Frontier IP's holds a 3.3 per cent equity stake in
Exscientia.
Exscientia statement in full:
SRI International and Exscientia Enter Collaboration to
Accelerate Drug Discovery Through Automation and Artificial
Intelligence.
Companies will combine SynFini and Centaur Chemist platforms to
focus on small-molecule oncology target
MENLO PARK, Calif. and OXFORD, United Kingdom.
Exscientia, a clinical-stage Artificial Intelligence (AI)
drug-discovery company and SRI International (SRI), a research
center headquartered in Menlo Park, California announced today that
the companies have entered into a drug-discovery collaboration
agreement to implement a new approach to drug discovery by
integrating AI design with automated compound synthesis.
Through the collaboration, the companies will combine SRI's
fully automated SynFini(TM) synthetic-chemistry system with
Exscientia's Centaur Chemist(TM) AI platform to expedite discovery
of selective molecules for a high value oncology target.
"Both the SynFini and Centaur Chemist platforms have
demonstrated ability to overcome key drug discovery challenges,"
said Nathan Collins, Ph.D., chief strategy officer of SRI's
Biosciences Division and head of the SynFini program. "We believe
there is tremendous potential to further accelerate the oncology
drug-discovery process by combining these novel and proven
technologies."
SRI's end-to-end SynFini platform automates the design, reaction
screening and optimization (RSO), and production of target
molecules. It was developed to bring new drugs to the clinic more
quickly and affordably by accelerating chemical discovery and
development. The SynFini closed-loop system comprises three
components that work seamlessly together: a software platform
(SynRoute(TM)), a reaction screening platform (SynJet(TM)), and a
multi-step flow chemistry automation and development platform
(AutoSyn(TM)).
Exscientia is the first company to successfully apply AI
technologies to design small molecule compounds that have reached
the clinic. Molecules generated by Exscientia's Centaur ChemistTM
platform are highly opitimised to satisfy the multiple pharmacology
criteria required to enter a compound into the clinic and to
achieve these goals in a revolutionary time scale. Centaur Chemist
transforms drug discovery into a formalized set of moves whilst
also allowing the system to learn strategy from human experts.
Andrew Hopkins, CEO of Exscientia said, "The opportunity to
apply AI drug design through our Centaur Chemist system with
SynFini automated chemistry offers an exciting opportunity to
accelerate drug discovery timelines through scientific innovation
and automation."
Exscientia statement ends
ENQUIRIES
Frontier IP Group Plc T: 020 7332 2338
Neil Crabb, Chief Executive neil@frontierip.co.uk
Andrew Johnson, Communications & Investor M: 07464 546 025
Relations
Company website: www.frontierip.co.uk
Allenby Capital Limited (Nominated Adviser) T: 0203 328 5656
Nick Athanas / Nicholas Chambers
Exscientia Limited
Mark Swindells, chief commercial officer contact@exscientia.ai
Edelman PR exscientia@edelman.com
Anitra Sprauten +44(0) 78 9685 9386
anitra.sprauten@edelman.com
NOTES FOR EDITORS
About Exscientia
Exscientia is a global Artificial Intelligence (AI)-driven drug
discovery company and the first to have novel chemical molecules
assessed in a clinical setting. Fusing the power of the original
AI-design with the experience of seasoned drug hunters,
Exscientia's Centaur Chemist(TM) platform enables the discovery of
exquisitely optimised molecules with breakthrough productivity.
In tandem, Exscientia's Centaur Biologist(TM) platform drives
the flexible analysis and prioritisation of discovery targets
across all pharmaceutically relevant disease space. For more
information visit us on www.exscientia.ai or follow us on Twitter
@exscientialtd.
ABOUT SRI INTERNATIONAL
SRI International, a non-profit research institute founded in
1946 and headquartered in Menlo Park, California, creates
world-changing solutions to make people safer, healthier, and more
productive. SRI Biosciences, a division of SRI International,
integrates basic biomedical research with drug and diagnostics
discovery, and preclinical and clinical development.
SRI Biosciences has produced several marketed drugs and advanced
more than 100 drugs to clinical trials. The division is focused on
novel platforms and programs in a variety of therapeutic areas
targeting high unmet medical needs. SRI Biosciences collaborates
with a broad range of partners from small and virtual biotechnology
companies to top 10 pharmaceutical companies and other leading
industry partners. More information is available at www.sri.com
.
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong
intellectual property and accelerating its development through a
range of commercialisation services. A critical part of the Group's
work is involving relevant industry partners at an early stage of
development to ensure technology meets real world demands and
needs.
The Group looks to build and grow a portfolio of equity stakes
and licence income by taking an active involvement in spin-out
companies, including support for fund raising and collaboration
with relevant industry partners at an early stage of
development.
ABOUT RNS REACH ANNOUNCEMENTS
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute media only /
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUNUNRRRUVRAR
(END) Dow Jones Newswires
May 07, 2020 02:00 ET (06:00 GMT)
Frontier Ip (LSE:FIPP)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Frontier Ip (LSE:FIPP)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
